MetaCap

Longeveron (LGVN) vs Universe Pharmaceuticals (UPC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Longeveron is the larger company by market cap ($5.6 million vs $5.4 million), about 1.0 times the size, while Universe Pharmaceuticals is growing revenue faster (-22.4% vs -49.9%). Universe Pharmaceuticals converts more of its revenue into profit, with a net margin of -20.6% versus -1893.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LGVN-31.97%UPC-74.91%
+41%-20%-80%
Oct 7, 20261 yearNov 20, 2026
LGVN-33.06%UPC-73.98%
+9%-35%-78%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LGVN versus UPC key metrics
MetricLGVNUPC
Share price$1.66$1.08
Market cap$5.60M$5.43M
1-day change-8.79%-20.59%
YTD return—-71.65%
1-year return—-68.24%
5-year return—-99.99%
EPS (TTM)$-7.95$-1.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.20M$17.86B
Revenue growth (YoY)-49.87%-22.44%
Net income (latest FY)$-22.70M$-3.67B
Gross margin66.97%35.28%
Operating margin-1942.20%-16.33%
Net margin-1893.58%-20.56%
52-week high$12.30$17.96
52-week low$1.31$1.05
Distance from 52-week high-86.50%-93.99%
Analyst consensusnone—
Avg. price target upside+3589.76%—
Average volume115.35K176.76K
Shares outstanding3.23M5.01M
Employees38216
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Universe Pharmaceuticals is more profitable, keeping -20.6 cents of every revenue dollar as net income versus -1893.6 cents for Longeveron.
  • Universe Pharmaceuticals grew revenue faster in its latest fiscal year (-22.44% vs -49.87%).

About Longeveron

LGVN stock →

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.

Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees

About Universe Pharmaceuticals

UPC stock →

Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications.

Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees

LGVN vs UPC FAQ

Which is bigger, Longeveron or Universe Pharmaceuticals?

Longeveron (LGVN) is larger, with a market capitalization of $5.60M compared with $5.43M for Universe Pharmaceuticals (UPC).

Are Longeveron and Universe Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons